Work

1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial

Year: 2016

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(16)30245-3

Authors: R. Rosell, S.N. Gettinger, L.A. Bazhenova, C.J. Langer, R. Salgia, A.T. Shaw, N.I. Narasimhan, D.J. Dorer, D. Kerstein, D.R. Camidge

Institutions: Institut Català d'Oncologia, Yale University, University of California San Diego, Moores Cancer Center, Abramson Cancer Center, University of Pennsylvania, University of Chicago, Massachusetts General Hospital, ARIAD Pharmaceuticals (United States), University of Colorado Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2337039403

FWCI: 6.881

Cites:

Cited by: 29

Related to: 10